Relapse of chronic myeloid leukemia (CML) as extramedullary granulocytic sarcoma (GS) after allogeneic bone marrow transplantation (BMT) is a rare occurrence. We report two patients who developed spinal GS as the first indication of relapse after allogeneic BMT for CML. In both cases, the marrow was in morphologic and karyotypic remission. However, fluorescence in situ hybridization (FISH) successfully demonstrated the presence of a minor Ph-positive clone in the marrow, as well as an occult clone with an additional Ph chromosome detected in one case. The results indicated a stronger graft-versus-leukemia effect in the marrow than in the peripheral tissues. Keywords: bone marrow transplantation; granulocytic sarcoma; chronic myeloid leukemia Bone marrow transplantation (BMT) is the only curative treatment for chronic myeloid leukemia (CML).
Bone marrow transplantation (BMT) is the only curative treatment for chronic myeloid leukemia (CML). 1 The successful elimination of the Philadelphia chromosome (Ph) positive clone is the most important therapeutic goal. This is achieved largely by the conditioning regimen, and partly by a putative graft-versus-leukemia (GVL) effect exerted by the allograft. 2 This is reflected by the lower rate of relapses in allogeneic as compared with syngeneic BMT. Furthermore, the abrogation of graft-versus-host disease by intense GVHD prophylaxis and T cell depletion leads to increased relapse rates, owing to a reduced GVL effect. 3 Extramedullary disease occurring as granulocytic sarcoma is an uncommon complication of CML in chronic phase or after BMT. In previous reports of GS post-BMT, it has been shown that the leukemic cells originated from the original CML clone. 4, 5 We report two patients with isolated blastic transformation in the form of GS postallogeneic BMT for CML. 
Materials and methods

Histological, immunocytochemical, cytogenetic and fluorescence in situ hybridization studies
Bone marrow assessment of CML was performed according to standard criteria. Histologic examination of biopsy specimens was performed on hematoxylin and eosinstained sections. Immunophenotyping for the expression of CD3, CD20, CD45, myeloperoxidase (MPO), CD56 and terminal deoxynucleotidyl transferase (TdT) was performed for cases 1 and 2, and additionally for CD13, CD19, CD22 and CD33 in case 2. Cytogenetic analysis was performed on fluorodeoxyuridine-synchronized overnight culture of marrow cells. Metaphase chromosomes were banded by Wright-Giemsa and karyotyped according to ISCN 1995. Interphase fluorescence in situ hybridization (FISH) was performed with an MBCR/ABL probe mix (Oncor, Gaithersburg, MD, USA) according to the manufacturer's instruction. Conditions of hybridization and post-hybridization washing were as described. 6 Hybridization signals were evaluated with an image analysis system (Cytavision; Applied Imaging, Sunderland, UK).
Case reports and results
Case 1
In September 1990 a 29-year-old Chinese man received an allogeneic BMT from an HLA-identical sister for CML in chronic phase. Cy-TBI (cyclophosphamide 120 mg/kg, total body irradiation 12 Gy) was used as conditioning and CsA (intravenous cyclosporin A 2 mg/kg/day from day −1) and MTX (methotrexate 15 mg/m 2 on day 1, 10 mg/m 2 on days 3, 6 and 11) were used as GVHD prophylaxis. He engrafted on day 20 with grade II acute GVHD affecting his skin, gut and liver. There was no chronic GVHD and CsA was stopped. Cytogenetic analysis on day 90 showed 100% Phpositive cells (Table 1 ). The patient was given interferon (IFN, 6 megaunits three times a week) for 11 months. There was a transient cytogenetic response, following by emergence of 8% of cells with trisomy 8 (Table 1) . A second BMT was performed from the same donor, using Bu (busulphan 16 mg/kg)-Cy as conditioning. To augment the GVL effect, CsA was omitted and MTX was used alone as 100 GVHD prophylaxis. He engrafted on day 20 with grade I GVHD of the liver. There was no evidence of chronic GVHD. He remained pancytopenic and on day 133 was admitted with a large tumor that extended from the L1-L3 lumbar vertebrae to the right psoas muscle. A needle biopsy performed under radiologic guidance showed diffuse infiltration by blasts with fine chromatin and scanty cytoplasm. The blasts were positive for CD45, but negative for B and T cell markers, as well as CD56. A diagnosis of localized blastic transformation as GS was made. At this time, although marrow karyotypic analysis showed only donor metaphases, FISH analysis showed a small clone (7.5%) of Ph positive cells ( Table 1 ). The GS responded to radiotherapy and combination chemotherapy (intravenous cytosine arabinoside 100 mg/m 2 × 5, oral thioguanine 75 mg/m 2 × 5). However, the patient died of neutropenic sepsis 1 month later. Post-mortem examination was refused.
Case 2
A 41-year-old Chinese man underwent an allogeneic BMT from an HLA-identical sister for CML in accelerated phase in September 1992. Bu-Cy-TBI (busulphan 7 mg/kg, cyclophosphamide 50 mg/kg, TBI 12 Gy) was used as conditioning, and CsA and MTX as GVHD prophylaxis. He engrafted on day 21. Grade I acute GVHD developed on day 50 and prednisolone 1 mg/kg was added. The day 66 marrow showed 38% Ph-positive metaphases (Table 1) . On sudden withdrawal of steroids and CsA, severe grade IV GVHD developed on day 94, necessitating treatment with steroids, CsA and antithymocyte globulin. This was followed by mild chronic GVHD requiring treatment with prednisolone and azathioprine. A bone marrow biopsy done at 12 months showed morphologically normal marrow and 100% donor metaphases. Fifteen months afterwards, he presented with cord compression and magnetic resonance scanning revealed an extradural mass completely destroying the T10 vertebral body. An open biopsy showed GS, with blasts positive for CD45, CD13 and MPO, and negative for other lymphoid markers. Local radiotherapy was given. A reassessment marrow still showed normal donor metaphases. The patient died of a chest infection 2 months later. Post-mortem examination was refused. Retrospective analysis of his marrow by FISH showed that immediately after BMT there was persistence of the Phpositive clone, as also demonstrated by conventional karyotyping. More importantly, however, FISH revealed a clone with duplicated BCR/ABL fusion that was not shown on karyotypic analysis (Table 1) . This is typically found in CML in acceleration. 7 The withdrawal of GVHD treatment resulted in an apparent cytogenetic remission (Table 1) . However, FISH still showed persistence of both the Ph and duplicated Ph clones (Figure 1) . Although there was a gradual decline of both abnormal clones, the presence of the clone of duplicated Ph heralded the blastic transformation, and GS ultimately developed. CP = chronic phase; AP = accelerated phase; BC = blastic crisis; RT = radiotherapy; chemo = chemotherapy; NA = not available; Sib = sibling; L = lumbar; T = thoracic.
Discussion
Isolated relapse of CML as extramedullary GS after BMT is a rare occurrence. A recent European Bone Marrow Transplantation Registry multicenter study identified only five such cases (0.21%) out of a total of 2346 patients. 8 Our two patients were found among a cohort of 74 patients undergoing BMT for CML (unpublished data), so that the frequency is 2.7%. A review of seven reported cases 4, 5, 8 ( Table 2) showed that the most important risk factor was advanced disease at transplantation. Of interest is that in seven of nine cases, the musculoskeletal system was the site of recurrence, with the spine and the adjacent tissues being the most frequent site of involvement (three of seven cases). In our cases, an apparent cytogenetic remission was achieved in the marrow with augmentation of a potential GVL effect by reduction of the anti-GVHD treatment. At GS relapse, cytogenetic analysis of the marrow did not show the presence of the Ph-positive clone. On the other hand, FISH in both cases showed the persistence of the Ph-positive clone. Furthermore, an occult clone with duplicated Ph chromosomes was also demonstrated in one case. These findings highlight the importance of sensitive techniques such as FISH or the polymerase chain reaction in defining the Ph clone, as normal morphology and metaphase cytogenetics do not exclude residual disease. The FISH results notwithstanding, the augmentation of GVL did result in a significant suppression of the Ph clone in the marrow, although this did not prevent the final development of extramedullary GS.
Our observations raised some interesting points. The frequent occurrence of GS in the spine and paraspinal tissues might indicate that these are relative 'sanctuary sites' for the conditioning chemo-radiotherapy. However, this does not explain why blastic transformation selectively occurred at these sites, particularly when minimal residual disease could still be demonstrated in the marrow. Furthermore, in our cases, a continuous suppression of the Ph-positive clone was demonstrable in the marrow. Such findings may indicate a stronger GVL effect in the marrow than in the peripheral tissues. This might be attributable to an absence of GVL effector cells in other bodily tissues, or the lack of a suitable milieu of cytokines or other molecules for the effector cells to function maximally. 9 Similar observations of isolated recurrent extramedullary relapses as GS with apparently uninvolved marrow have also been made in patients with acute myeloid leukemia after allogeneic BMT. 10 The prognosis of GS post-BMT for CML is poor, and mortality has been reported in all but one patient. Systemic immunological manipulations, including the use of interferon and donor lymphocyte infusions, 11 have been shown to be effective in suppressing the Ph-positive clone in the marrow. Whether they are effective in extramedullary GS is unknown and should be investigated. However, the possibility that the GVL effect could be weaker in peripheral tissues may imply that local and/or systemic anti-leukemic treatments should also be administered.
